KDM2B and glioblastoma: Importantly, the impact of KDM2B loss or inhibition on the survival and DNA repair capacity of GBM cells is further potentiated when combined with either lomustine (CCNU) or etoposide (VP‐16), chemotherapeutics routinely used in therapeutic management of recurrent disease (Taal et al., 2014; Wick et al., 2017).